




- (51) International Patent Classification:
C07K 16/30 (2006.01)
- (21) International Application Number:
PCT/US2021/022847
- (22) International Filing Date:
17 March 2021 (17.03.2021)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
62/991,042 17 March 2020 (17.03.2020) US
- (71) Applicants: SYSTIMMUNE, INC. [US/US]; 15318 NE 95th St, Redmond, Washington 98052 (US). SICHUAN BAILI PHARMACEUTICAL CO. LTD. [CN/CN]; 161 Baili Road, Wenjiang District, Chengdu, Sichuan (CN).
- (72) Inventors: ZHU, Yi; 15318 NE 95th Street, Redmond, Washington 98052 (US). CHATTERJEE, Soumili; 19505 25th Dr SE, Bothell, Washington 98012 (US). GOULET, Dennis R.; 6788 138th Ave NE #626, Redmond, Washington 98052 (US). TSAI, Tsung-I; 15810 NE 67th Pl, Redmond, Washington 98052 (US). RENSCHAW, Blair; 16210 SE 166th Ct, Renton, Washington 98058 (US). VINCENT, Christopher G.; 19318 8th Ave. W., Lynnwood, Washington 98036 (US). WAIGHT, Andrew; 8442 NE169th Place, Kenmore, Washington 98028 (US). MAK, Nga Sze Amanda; 9752 Marine View Dr, Mukilteo, Washington 98275 (US).
- (74) Agent: HAN, Zhihua; EpiMED LLC, 10398 NE 17th St. Unit 306, Bellevue, Washington 98004 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

(54) Title: MINIATURE GUIDANCE AND NAVIGATION CONTROL (miniGNC) ANTIBODY-LIKE PROTEINS AND METHODS OF MAKING AND USING THEREOF

Figure 1



(57) Abstract: A multi-specific antibody-like protein having a first monomer comprising a first binding monomer, a CH1 domain, a first hinge, a first CH2 domain, and a first CH3 domain, a second monomer comprising a second binding monomer, a CL domain, a second hinge, a second CH2 domain, and a second CH3 domain, wherein the first binding monomer and a second binding monomer are configured to form a dimer, wherein the first monomer and the second monomer are covalently paired through at least one disulfide bond between the CH1 domain and the CL domain and at least one disulfide bond between the first hinge and the second hinge, wherein the first monomer and second monomer may comprise optionally a first binding domain (D1) and a second binding domain (D2), and a fourth binding domain (D4) and a fifth binding domain (D5), and wherein the multi-specific antibody-like protein is at least bi-specific.

[Continued on next page]

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
 - *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
 - *with sequence listing part of description (Rule 5.2(a))*
-